Assembly BiosciencesASMB +10.25%32 PB Ratio is 2.14 as of Jun. 27, 2026, which is 3% below its 10-year median of 2.21. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Assembly Biosciences ranks better than 63.56% on this metric.
The historical rank and industry rank for Assembly Biosciences's PB Ratio or its related term are showing as below:
ASMB'
s PB Ratio Range Over the Past 10 Years
Min: 0.28 Med: 2.21 Max: 17.76
Current: 2.14
During the past 13 years, Assembly Biosciences's highest PB Ratio was 17.76. The lowest was 0.28. And the median was 2.21.
ASMB's PB Ratio is ranked better than 63.56% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ASMB: 2.14
During the past 12 months, Assembly Biosciences's average Book Value Per Share Growth Rate was 250.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -38.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -23.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Assembly Biosciences was 21.90% per year. The lowest was -55.50% per year. And the median was -12.00% per year.
Back to Basics: PB Ratio
Assembly Biosciences (NAS:ASMB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Assembly Biosciences PB Ratio Related Terms
Assembly Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Assembly Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Assembly Biosciences (ASMB) has a PB Ratio of 2.14 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Assembly Biosciences and its competitors. This is near median its historical median of 2.21. Over the past decade, Assembly Biosciences' PB Ratio has ranged from 0.28 to 17.76. According to the industry distribution chart, Assembly Biosciences ranks #449 out of 1232 companies in the Biotechnology industry, placing it in the top 36.4%.
Is Assembly Biosciences' PB Ratio too high?
Assembly Biosciences' current PB Ratio of 2.14 is near median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 17.76. The Biotechnology industry median PB Ratio is 2.80. Assembly Biosciences' value of 2.14 is 23.6% below this industry median. Based on the distribution chart, Assembly Biosciences ranks #449 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' PB Ratio compare to MDXG and AGMB?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #449 out of 1232 companies for PB Ratio. This puts Assembly Biosciences in the upper half of its industry. The industry median PB Ratio is 2.80. Assembly Biosciences' value of 2.14 is 23.6% below this benchmark. Historically, Assembly Biosciences' own PB Ratio has ranged from 0.28 to 17.76 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 2.80, Assembly Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current PB Ratio of 2.14 is 23.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current PB Ratio is 2.14, which is near median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current PB Ratio of 2.14. The current PB Ratio is 2.14, which is near median its 10-year median of 2.21 and 23.6% below the Biotechnology industry median of 2.80. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current PB Ratio is 2.14 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
